Synektik_presentation_H1_2023 r._EN final.pptx

SYNEKTIK SA Synektik SA | Investor Presentation Q1 2024 FY

1. SYNEKTIK S.A. Investor Presentation H1 2023 FY June 2024

2. Synektik in snapshot 2 H1 FY 2023 Financial results | Investor presentation Company profile Integrator of innovative solutions for medicine Largest manufacturer and supplier of radiopharmaceuticals in Poland Research and Development Centre focused on developing innovative molecules and radiopharmaceutical products Developer of special medical software and applications Leading supplier of advanced medical technologies Provider of maintenance and measurement services Indexes WIG, sWIG80, WIGTECH, WIG-Poland ISIN PLSNKTK0001 Number of shares 8 529 129 Capitalisation (1) PLN 1.23bn Enterprise value (2) PLN 1.18bn P/E (3) 13.1 EV/EBITDA (4) 8.7 Market capitalisation and ratios calculated as of 7 June 202 4 Enterprise value = market capitalisation as of 1 7 June 202 4 + net debt as of 3 1 March 2024 Net profit adjusted for one-off items EBITDA adjusted for one-off items PLN 359 m REVENUE FROM SALES, H1 FY2023 PLN 79 m AJDUSTED EBITDA H1 FY2023

3. Highlights of Q2 FY2023 Sales of equipment and IT solutions – growing recurring revenue , expansion of the offer 37% increase in revenue in Q2 FY 2023, to PLN 75.1 million ; increase in recurring revenue by 61%, to PLN 46.8 million Expansion of cooperation with Insightec for the exclusive sale of the Exablate Neuro system to the markets of the Czech Republic and Slovakia Establishment of cooperation with Medical Microinstruments . GK Synektik has become the exclusive distributor of Symani microsurgery systems in Poland, the Czech Republic, Slovakia, Lithuania, Latvia, and Estonia. Radiopharmaceuticals – growth in revenues and profitability PLN 12.6 million in revenue (excluding intra-group transactions) in Q2 FY2023 , up 17 % y/y Record-high sale of of essential radiopharmaceuticals - PLN 5.7 million , up 17 % y/y 35% EBITDA margin ( increase by 5 percentage points ) R&D – selection of a proprietary molecule , technology transfer to partners in the USA Decision to continue the project based solely on the molecule in respect of which 100% of intellectual property rights and patent protection belong to the Synektik Group Preparations to launch clinical trials in the United States, technology transfer in progress

4. 4 H1 FY 2023 Financial results | Investor presentation 37 % increase in total revenue from sales of equipment, IT solutions and the provision of services ( excluding intra-group transactions ) 17 % increase in revenue of the radiopharmaceuticals segment, excluding intra-group transactions Financial performance in Q2 FY2023 +34% +134% +101% 140 % increase in EBITDA of the equipment, IT and services segment, to PLN 23.4 mil l ion ; EBITDA margin at 23% 34 % increase in EBITDA of the radiopharmaceuticals segment, to PLN 4. 4 mi l lion , EBITDA margin at 38% Doubling of adjusted net profit

5. PLN +14.6m Change in adjusted EBITDA PLN, million PLN, million PLN, million

6. 6 H1 FY 2023 Financial results | Investor presentation 76 % increase in total revenue from sales of equipment, IT solutions and the provision of services ( excluding intra-group transactions ), to PLN 336.5m 23 % increase in revenue of the radiopharmaceuticals segment, excluding intra-group transactions , to PLN 22.5m Financial performance in H1 FY2023 +71% +93% +85% 91 % increase in EBITDA of the equipment, IT and services segment, to PLN 76.6 mil l ion 80 % increase in EBITDA of the radiopharmaceuticals segment, to PLN 8.5 mi l lion 85% increase of adjusted net results PLN 3.1 million of negative balance of financ e income and costs, change by PLN -4 million

7. 53.1 25.5 Group’s adjusted E BITDA i n FY 2020-2023 Summary 121 % increase in adjusted EBITDA for past 4 quarters, to PLN 135.3 million at 31.03.2024 EBITDA growth driven by: increase in sales of equipment used in therapy growing scale of recurring sales in both segments impact of operating leverage achieved thanks to a significant increase in the scale of the Group's activities

8. Group’s recurring sales i n FY 2020-2023 Dynamic growth of recurring revenue Drivers: Dynamically increasing demand for consumable parts and accessories for therapy equipment sold by the Synektik Group I ncrease in the value of post-warranty support services for the offered medical equipment Increase in the value of IT and measurement services provided Increase in demand for radiopharmaceuticals used in PET/CT examinations

9. Selected financial data PLN 000s Q2 FY 2023 Q2 FY 2022 H1 FY 2023 H1 FY 2022 Sales revenue 87 703 65 663 358 999 209 478 EBIT 16 610 3 183 61 977 27 811 EBIT margin 19% 5% 17% 13% Adjusted EBITDA 25 517 10 906 78 662 40 682 EBITDA margin 29% 17% 22% 19% Net profit 12 234 4 029 46 903 23 113 PLN 000s 31.03.2024 30.09.2023 Non-current assets, including: 142 968 131 291 Property, plant and equipment 47 133 37 663 Other intangible assets 45 642 50 345 Current assets, including: 179 580 168 624 Inventories 31 568 21 273 Trade receivables 71 487 79 659 Cash 71 629 62 663 Equity 154 373 134 201 Non-current liabilities 42 111 47 481 Liabilities under bank loans and borrowings - - Lease liabilities 13 622 13 848 Trade and other liabilities 83 988 90 819 Current liabilities, including: 126 065 118 233 Liabilities under bank loans and borrowings - 1 300 Lease liabilities 3 980 3 573 Trade and other liabilities 4 196 11 580 Net debt (54 027) (43 942) Total cash flow, including : 8 996 16 283 Operating cash flow 48 788 48 094 Surplus of cash over financial liabilities of PLN 54 million on 3 1 March 202 4 Increase in trade payables related to d eferred revenue s increase , related to the settlement of service contracts and the supply of consumables for therapeutic equipment. PLN 48.8 million in positive operating cash flow in H 1 FY2023 PLN 9.0 million in positive total cash flow s ( including dividend payout : PLN 25.8 million )

10. 10 H1 FY 2023 Financial results | Investor presentation SYNEKTIK S.A. Medical equipment and IT solutions

11. Key information Synektik is a leading provider of medical equipment and IT solutions used in radiology, oncology, cardiology and neurology Core areas : Sale of medical equipment from several leading manufacturers, used in radiology, therapy and nuclear medicine Preparation and equipment for operating rooms (OR) and diagnostic or radiology centres Development of medical software and sale of licenses in the field of archiving and distribution of radiological images, teleradiology and administrative data Supply of specialist diagnostic and maintenance stations Maintenance and measurement services for medical equipment Innovative project: platform Zbadani.pl Medical equipment and IT solutions

12. 12 Medical equipment and IT solutions Rapid growth in revenues and profits 76 % y/y increase in revenue s in H 1 FY2023, to PLN 336.5 million 91 % y/y increase in adjusted EBITDA in H 1 FY2023, to PLN 76.6 million PLN 247.5 million revenue from sales of medical equipment in H 1 FY2023 (PLN 140.8 million the year before) 77 % increase in recurring revenue from sales of services (repair and maintenance, warranty, IT) and supplies of consumable instruments and accessories in H 1 FY2023, to PLN 89.0 million 146% CAGR of recurring revenues (for last 12 months ) in last 2 years , to PLN 151.6 million +146% CAGR

13. 13 Medical equipment and IT solutions Very good prospects for H2 FY2023 Acquisition of orders worth PLN 191.6 million in H 1 FY2023, including for the delivery of: ZAP-X system 1 5 da Vinci systems set of equipment for diagnostic imaging Total value of the backlog at the end of H1 FY2023: PLN 19.1 million compared to PLN 72.1 million as at 31 March 202 3 Contract conclusion , in Q3 FY2023, for the supply of da Vinci systems with: hospital in Pilzno, worth USD 3.9 million Orlowski hospital in Warsaw, worth PLN 15 milion hospital in Havířov , worth USD 4.2 million University Hospital in Gdańsk, worth PLN 8.9 milion ( lease ) Contract conclusion (a s a member of the c onsortium ) for the supply of, among others , two angiography systems , worth PLN 17.7 million Placing a bid for the supply of da Vinci system for National Medical Institute of the Ministry of the Interior and Administration in Warsaw

14. 14 Da Vinci in Poland Medical equipment and IT solutions Nearly 2, 8 00 da Vinci assisted procedures in Q 2 FY2023 (up 102 % y/y), 8 , 4 00 in the last 4 quarters (up + 98 % y/y) Positive impact of i ntroduction ( starting from September 2023) of dedicated reimbursement for two more therapeutic areas – treatment of endometrial cancer and colorectal cancer Surgical procedures market: In 2023, 20% of all prostatectomy procedures were performed with da Vinci assistance, compared to 85-90% in Western countries. The share of da Vinci-assisted procedures in the total number of procedures with dedicated da Vinci reimbursement (prostate, colorectal, uterine cancers) is 5-10%. Installation in H 1 FY2023 of 11 da Vinci systems for Polish customers Market growth outlook according to a PMR report ( Rynek robotyki chirurgicznej w Polsce 2023 ): 80+ new robotic installations over the next 5 years, 43,000 assisted procedures in 2028

15. 15 Da Vinci in Czech Republik and Slovakia Medical equipment and IT solutions Over 2 , 3 00 da Vinci assisted procedures in Q 2 FY202 3 (up 28 % y/y), 8 , 00 in the last 4 quarters (up 31 % y/y) Installation in H1 FY202 3 of 5 da Vinci systems for Czech customers

16. * Being serviced by Synektik, including systems leased from Synektik 43 da Vinci systems in Poland* 30 da Vinci systems in Czech Republic and Slovakia * Q1 2024 Q1 2024 Medical equipment and IT solutions Da Vinci serviced by GK Synektik Warszawa Wrocław Białystok Poznań Kraków Siedlce Wieliszew Szczecin Gdańsk Gorzów Wlkp. Lublin Gdynia Katowice Bydgoszcz Rzeszów Łódź Toruń Usti nad Labem Pilzno Ceske Budejovice Hradec Kralove Velke Meziricí Brno Novy Jicin Ołomuniec Banska Bystrica Ostrava Praga Martin Jihlawa Liberec Bratysława Koszyce Kielce Leszno Zlin Częstochowa Słupsk Zielona Góra Olsztyn Pardubice Zabrze

17. 17 Medical equipment and IT solutions Symani. Synektik will robotize microsurgery Cooperation agreement with Medical Microinstruments for the sale of Symani, robotic systems for microsurgery: Synektik becomes the sole distributor of systems in Poland, the Czech Republic, Slovakia, and the Baltic countries (Lithuania, Latvia, Estonia) Synektik will be responsible for sales and servicing of robots, instruments for the mentioned devices, operator training for the systems, regulatory and marketing issues The agreement is valid for a period of 3 years with the possibility of extension for another 3 years CMM – cart with macropositioner and micromanipulators Surgical Control Console NanoWrist ® - 3 mm wristed instruments

18. Lymphatic surgery Lymphatic system Lymphovenous Bypass Lymphaticovenous anastomosis (LVA) Transfer of vascularized lymph nodes ( lymphatic transplant) Vascularized Omental Flap Transfer 18 Medical equipment and IT solutions Symani applications Vascular reconstruction Restoration of blood flow Reconstructive flaps Injury / Replantations Microsurgical vessel repair Peripheral nerve reconstruction Regaining sensation Brachial Plexus Nerve repair (End-to-End Anastomosis ) Nerve Grafts Nerve transfers

19. 19 Medical equipment and IT solutions Exclusive distribution agreement for Qure.ai technology: Synektik becomes the sole software distributor in Poland, the Czech Republic, and Slovakia The agreement is valid for a period of 3 years from October 1, 2024, with the possibility of extension for another 3 years By September 30th of the current year, Synektik will assess the potential for effective implementation of Qure.ai technology in medical and telemedical facilities on a large scale. The analysis results will be the basis for further cooperation decisions The company plans to include Qure.ai in the Zbadani.pl platform offering Qure.AI will strengthen Zbadani.pl

20. 80+ Countries 2000+ Sites 200m Images processed annually Largest training data sets and repository of +1Bn images Multiple FDA and CE clearances Results available in 30 sec 200+ employees, 100+ AI Scientists & Engineer Used for evaluation of radiological studies, CT scans, and mammography Medical equipment and IT solutions Q ure.AI. Key informations

21. Online Delivery of Imaging Results Sharing Medical Documentation AI in Imaging Diagnostics Patient Portal AI SynDose Dose Registry Medical equipment and IT solutions Z badani.pl – p roducts and s ervices for m edical f acilities and p atients

22. The patient receives the imaging result Creating a Digital Patient File Ordering a study report via AI Teleconsultation on the Zbadani.pl platform The patient receives a secure link to the imaging study on their phone or email; Once the report is ready, it is sent via a secure link through SMS/email. The patient is invited to create an account on the Patient Portal, where they can store their imaging studies in the Digital Patient File and share them with any specialist worldwide and/or consult via telemedicine on Zbadani.pl. Coming soon - The patient will be able to order an analysis and imaging study report via AI in less than 1 minute. Within the platform, the patient has access to numerous specialists with whom they can arrange teleconsultations and discuss their studies. Medical equipment and IT solutions Z badani.pl – development plans AI

23. SYNEKTIK S.A. Radiopharmaceuticals 23 H1 FY 2023 Financial results | Investor presentation

24. Key information Radiopharmaceuticals 50+ Number of employees Synektik Group products by diagnostic application Wide spectrum of tumours Prostate tumours Bladder tumours Parkinson's disease , neuroendocrine tumours Brain and extracranial tumours Breast and reproductive organ tumours Bone tumours Cholina FDG FLT PSMA Cholina FES FET DOPA Metaflu Axumin Synektik is the largest producer and supplier of PET/CT radiopharmaceuticals in Poland Major producer of special radiopharmaceuticals 3 Production sites together with R&D Centre Location of cyclotrons for the production of radiopharmaceuticals used in PET studies Owned by Synektik Public Private Source: Own compilation based on data from the Supreme Audit Office, https://www.nik.gov.pl/aktualnosci/niecertyfikowane-radiofarmaceutyki.html (30.11.2021)

25. Radiopharmaceuticals Growing revenues and margins 23 % y/y increase in sales in H 1 FY2023, to PLN 22.5 million 35 % increase in sales of basic tracers, to PLN 11.6 mil l ion , a result of a rise in the number of tests and changes in selling prices 1 2 % increase in sales of specialty tracers, to PLN 4.1 million 8 % increase in EBITDA, to PLN 8.5 million Increase in the segment’s EBITDA profitability from 26 % in H 1 FY2022 to 38 % in H 1 FY2023)

26. SYNEKTIK S.A. Cardiotracer 26 H1 FY 2023 Financial results | Investor presentation

27. Cardiotracer COMPETITIVE ADVANTAGES: Better image resolution and contrast Lower dose of radiation Quantitative analysis of myocardial blood supply in absolute terms Ability to image so-called difficult patients Shorter radiation retention time [1] DISCOVERY [2] PRE-TRIAL PHASE [3] CLINICAL TRIALS [4] APPROVAL BY THE FDA AND THE EMA PHASE I PHASE II PHASE III IN VIVO, IN VITRO TRIALS SAFETY OF USE, DOSIMETRY COMPARISON OF EFFICIENCY INVESTMENT COST RISK CARDIO PET MARKER Lead structure discovery, synthesis, evaluation HERE WE ARE Preparations to launch clinical trials in the United States, technology transfer in progress Decision to continue the project based solely on the molecule in respect of which 100% of intellectual property rights and patent protection belong to the Synektik Group. Signing of an agreement with Hadasit to terminate cooperation Patent protection obtained in Japan

28. SYNEKTIK S.A. Q&A SESSION 28 H1 FY 2023 Financial results | Investor presentation

29. Thank You ! Cezary Kozanecki President of the Management Board , CEO [email protected] Dariusz Korecki Vice- President of the Management Board , CFO [email protected]